Nuvectis Pharma, Inc. (NVCT) stock
Close on Nov 11, 2026Market cap $684.21MP/E –Yield 0.00%
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $684.21M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.40
- Dividend yield
- 0.00%
- Free cash flow yield
- –
Fundamentals
- Net income
- -$50.45M
- EPS, diluted
- -$1.90
- Book value per share
- $4.30
- Diluted shares
- 29M
Trading
- Next earnings
- Feb 10, 2027 (estimated, before the open)
- Previous close
- $21.08
- Open
- $21.31
- Day's range
- $20.60 – $21.78
- Volume
- 153,124
- Average volume (20 days)
- 204,783
- Index membership
- Russell 2000 (since Jun 2025)
- Beta (5 years)
- 0.49
- 52-week range
- $5.77 – $29.27
- RSI (14 days)
- 56.4
- Volatility (1 year)
- 86.6%
- Relative volume
- 0.71×
- WACC
- 7.4%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | NVCT | S&P 500 | Difference | NVCT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -0.6% | -2.4% | +1.8 pts | ||
| 3 months | +8.2% | -1.2% | +9.3 pts | ||
| Year to date | +178.1% | +12.3% | +165.9 pts | ||
| 1 year | +246.5% | +12.4% | +234.1 pts | ||
| 3 years | +160.5% | +78.8% | +81.7 pts | +37.6% | +21.4% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases Nuvectis Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- News
- News
- Results
About Nuvectis Pharma
Pharmaceutical Preparations
Nuvectis Pharma is a clinical-stage biopharmaceutical company that develops precision therapeutics for serious cancer conditions. Its lead product candidate is NXP900, an oral small-molecule targeted inhibitor of SRC and YES1 kinases currently evaluated in clinical trials for advanced solid tumors. The firm previously evaluated another oncology candidate, NXP800, before halting its clinical development. As an early-stage development business with no commercialized treatments, the company does not operate commercial sales segments or serve end consumers; its drug candidates are tested in cancer patients enrolled in clinical trials.
Company profile, executives and historyNuvectis Pharma stock: common questions
What is Nuvectis Pharma's stock price?
NVCT closed at $21.00 on Nov 11, 2026, down 0.38% on the day. Over the past 52 weeks it traded between $5.77 and $29.27.
What is Nuvectis Pharma's market cap?
Nuvectis Pharma was worth $684.21M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is NVCT's P/E ratio?
Nuvectis Pharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.90), so it has no meaningful P/E ratio.
Does Nuvectis Pharma pay a dividend?
No. Nuvectis Pharma has not paid a cash dividend over the last twelve months.
When does Nuvectis Pharma report earnings next?
Nuvectis Pharma is expected to report Q4 FY2026 results on Feb 10, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has NVCT stock performed over the past year?
Including dividends, NVCT returned +246.5% over the past year, against +12.4% for the S&P 500.
How many NVCT shares are sold short?
3M shares were sold short at the latest FINRA report, 12.00% of the float, or 15.2 days of average trading volume.
Who are Nuvectis Pharma's competitors?
Companies most similar to Nuvectis Pharma by business, industry and size include ZNTL, CRBP, AVBP, NUVB, RCUS.
See a number that looks wrong?